** Shares of Cleo Diagnostics COV.AX rise as much as 17.7% to A$0.400, their highest level since May 5
** Stock set for its best day since April 14, if trends sustain
** The cancer diagnostics tests provider receives approval from U.S. National Cancer Institute to access blood samples from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial
** Around 209,750 shares change hands, busiest day since May 19
** Stock up 4.2%, YTD
(Reporting by Keshav Singh Chundawat in Bengaluru)
((Keshav.SinghChundawat@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.